CHRS - Why Coherus BioSciences Stock Is Climbing Today | Benzinga
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody.
The Details:
Coherus BioSciences announced the approval of its Udenyca Onbody delivery device after the market close on Tuesday.
"The on-body injector for Udenyca is the result of years of significant investment in ...